If you have been or are thinking about getting into AbbVie (NYSE: ABBV), there is still time to do so. The AbbVie stock price is in a sustained uptrend and will set new all-time highs repeatedly over time. The reason why is simple: This is an incredibly well-run company with foresightful management that has positioned it for success.
Once reliant on Humira for revenue, margin, and profits, it is now a well-diversified pharmaceutical company with a quiver filled with blockbuster hits. The critical takeaway is that it, like its parent, Abbott Laboratories, is a healthy capital-returning machine on track to pay substantial dividends while buying back shares and maintaining a fortress position.
